Cytokine Release Assay

Cytokine release assays quantitate pro-inflammatory mediator production by immune cells in response to pharmaceutical exposures or microbial antigens, serving as sensitive biomarkers for immune activation and pyrogenicity. Whole-blood assays measure interferon-gamma, tumour necrosis factor-alpha, and interleukin-6 release from stimulated leukocytes enabling rapid pyrogenic response assessment. These assays replace traditional rabbit pyrogenicity tests providing greater sensitivity, reduced animal use, and faster turnaround. Monocyte activation assays detect endotoxin responses predicting inflammatory responses to parenteral pharmaceuticals.

Cytokine release monitoring extends clinical utility as biomarker for immunotoxicity, immune checkpoint modulator-associated immune-related adverse events, and immune engagement confirmation for immunotherapeutics. Elevated baseline cytokine production identifies inflammatory disease states potentially compromising treatment response. Longitudinal monitoring during immunotherapy detects cytokine elevation preceding overt adverse events enabling proactive clinical management. Advanced multiplexing techniques simultaneously quantitate numerous cytokines providing comprehensive immune response profiling. Regulatory acceptance of cytokine release data increasingly supports replacement of traditional pyrogenicity testing expediting pharmaceutical development timelines.